Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Arthritis Research & Therapy2011Vol. 13(3), pp. R105–R105
Citations Over TimeTop 10% of 2011 papers
Émilie Ducourau, Denis Mulleman, Gilles Paintaud, Delphine Miow Lin, Francine Lauféron, David Ternant, Hervé Watier, Philippe Goupille
Abstract
High concentrations of infliximab during treatment initiation reduce the development of ATI, and the absence of ATI may be associated with prolonged maintenance of infliximab. Thus, trough serum infliximab concentration should be monitored early in patients with rheumatic diseases.
Related Papers
- → Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study(2011)41 cited
- Current and future applications of SPECT in clinical psychiatry.(1992)
- [Management of failure of infliximab in inflammatory bowel disease].(2011)
- Types Research of Discontinuation of a Crime(2007)